T M Petrella1, G G Fletcher2, G Knight3, E McWhirter4, S Rajagopal5, X Song6, T D Baetz7. 1. University of Toronto and Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. 2. Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), and Department of Oncology, McMaster University, Hamilton, ON. 3. Department of Oncology, McMaster University, Hamilton, and Grand River Regional Cancer Centre, Kitchener, ON. 4. Department of Oncology, Division of Medical Oncology, McMaster University, and Juravinski Cancer Centre, Hamilton, ON. 5. Credit Valley Hospital, Mississauga, ON. 6. Department of Internal Medicine, Division of Medical Oncology, University of Ottawa, and The Ottawa Hospital Cancer Centre, Ottawa, ON. 7. Department of Oncology, Queen's University, and Cancer Centre of Southeastern Ontario-Kingston General Hospital, Kingston, ON.
Abstract
Background: Previous versions of the guideline from the Program in Evidence-Based Care (pebc) at Ontario Health (Cancer Care Ontario) recommended that the use of high-dose interferon alfa 2b therapy be discussed and offered to patients with resected cutaneous melanoma with a high risk of recurrence. Subsequently, several clinical trials in patients with resected or metastatic melanoma found that immune checkpoint inhibitors and targeted therapies have a benefit greater than that with interferon. It was therefore considered timely for an update to the guideline about adjuvant systemic therapy in melanoma. Methods: The present guideline was developed by the pebc and the Melanoma Disease Site Group (dsg). Based on a systematic review from a literature search conducted using medline, embase, and the Evidence Based Medicine Reviews databases for the period 1996 to 28 May 2019, the Working Group drafted recommendations. The systematic review and recommendations were then circulated to the Melanoma dsg and the pebc Report Approval Panel for internal review; the revised document underwent external review. Recommendations: For patients with completely resected cutaneous or mucosal melanoma with a high risk of recurrence, the recommended adjuvant therapies are nivolumab, pembrolizumab, or dabrafenib-trametinib for patients with BRAF V600E or V600K mutations; nivolumab or pembrolizumab are recommend for patients with BRAF wild-type disease. Use of ipilimumab is not recommended. Molecular testing should be conducted to help guide treatment decisions. Interferon alfa, chemotherapy regimens, vaccines, levamisole, bevacizumab, bacillus Calmette-Guérin, and isolated limb perfusion are not recommended for adjuvant treatment of cutaneous melanoma except as part of a clinical trial. 2020 Multimed Inc.
Background: Previous versions of the guideline from the Program in Evidence-Based Care (pebc) at Ontario Health (Cancer Care Ontario) recommended that the use of high-dose interferon alfa 2b therapy be discussed and offered to patients with resected cutaneous melanoma with a high risk of recurrence. Subsequently, several clinical trials in patients with resected or metastatic melanoma found that immune checkpoint inhibitors and targeted therapies have a benefit greater than that with interferon. It was therefore considered timely for an update to the guideline about adjuvant systemic therapy in melanoma. Methods: The present guideline was developed by the pebc and the Melanoma Disease Site Group (dsg). Based on a systematic review from a literature search conducted using medline, embase, and the Evidence Based Medicine Reviews databases for the period 1996 to 28 May 2019, the Working Group drafted recommendations. The systematic review and recommendations were then circulated to the Melanoma dsg and the pebc Report Approval Panel for internal review; the revised document underwent external review. Recommendations: For patients with completely resected cutaneous or mucosal melanoma with a high risk of recurrence, the recommended adjuvant therapies are nivolumab, pembrolizumab, or dabrafenib-trametinib for patients with BRAFV600E or V600K mutations; nivolumab or pembrolizumab are recommend for patients with BRAF wild-type disease. Use of ipilimumab is not recommended. Molecular testing should be conducted to help guide treatment decisions. Interferon alfa, chemotherapy regimens, vaccines, levamisole, bevacizumab, bacillus Calmette-Guérin, and isolated limb perfusion are not recommended for adjuvant treatment of cutaneous melanoma except as part of a clinical trial. 2020 Multimed Inc.
Authors: B Guillot; S Dalac; M G Denis; A Dupuy; J F Emile; A De La Fouchardiere; E Hindie; T Jouary; N Lassau; X Mirabel; S Piperno Neumann; S De Raucourt; R Vanwijck Journal: J Eur Acad Dermatol Venereol Date: 2017-01-24 Impact factor: 6.166
Authors: Benjamin A Lerner; Latoya A Stewart; David P Horowitz; Richard D Carvajal Journal: Oncology (Williston Park) Date: 2017-11-15 Impact factor: 2.990
Authors: Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Natalie J Ives; Stefan Suciu; Alexander M M Eggermont; John Kirkwood; Paul Lorigan; Svetomir N Markovic; Claus Garbe; Keith Wheatley Journal: Eur J Cancer Date: 2017-07-07 Impact factor: 9.162
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Melissa Thebeau; Krista Rubin; Matthias Hofmann; Julia Grimm; Alyona Weinstein; Jennifer N Choi Journal: J Am Assoc Nurse Pract Date: 2017-04-24 Impact factor: 1.165
Authors: Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson Journal: CA Cancer J Clin Date: 2017-10-13 Impact factor: 508.702
Authors: F C Wright; S Kellett; N J Look Hong; A Y Sun; T P Hanna; C Nessim; C A Giacomantonio; C F Temple-Oberle; X Song; T M Petrella Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677